2012 Press Releases

Onyx Pharmaceuticals International GmbH Appoints Luigi Costa as Vice President of Europe

Zug, Switzerland — Mar. 05, 2012

Onyx Pharmaceuticals International GmbH today announced that it has appointed Luigi Costa as Vice President and Head of Europe. Mr. Costa will report to Dr. Helen Torley, the Executive Vice President and Chief Commercial Officer of Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX).  In this key role, Mr. Costa will be responsible for building and leading Onyx’s commercialization efforts in Europe, developing the company’s European organizational structure and leading the commercial execution of growth initiatives to support the company’s globalization strategy.
 
“Luigi is a proven leader in the European biopharmaceutical arena,” said Dr. Torley. “His track record of success in growing established brands, such as Neulasta® and Aranesp®, and navigating the reimbursement environment to successfully launch new oncology products, will be key to Onyx’s development of our global commercialization plans and the potential launch of carfilzomib in Europe.”
 
“I am delighted to be joining Onyx at this exciting time,” said Mr. Costa. “I look forward to partnering with the team to establish Onyx’s European commercial presence and to help bring promising therapies, like carfilzomib, to patients throughout Europe as quickly as possible.”
 
Before joining Onyx, Mr. Costa spent eight years at Amgen where he most recently served as the Vice President and General Manager of France. Prior to this position, he held assignments as General Manager for Switzerland and Italy, as well as International Head of Nephrology and Oncology Franchise. From 1995 to 2003, he held various positions of increasing responsibility within Eli Lilly in the U.S. and Europe, including Business Unit Director and Global Pricing and Access Manager, based in Indianapolis. Mr. Costa received his Bachelors of Business Administration from the University of Parma, Italy, and his Masters of Business Administration from the SDA Bocconi and Manchester Business School, England.
 
About Onyx Pharmaceuticals
With global headquarters in South San Francisco, California, and European headquarters in Zug, Switzerland, Onyx Pharmaceuticals is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases. For more information about Onyx, visit the company's website at www.onyx.com.
 
Forward-Looking Statements
This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, the expanded access program, safety, regulatory processes, commercialization efforts or commercial potential of carfilzomib.  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the submission, review, potential approval of the NDA, development and commercialization of pharmaceutical products.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors.  Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release.  Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.